Stockscreener 앱 받기
5.54
4.53%
0.24
전일 마감가:
$5.30
열려 있는:
$5.6016
하루 거래량:
9,741
Relative Volume:
0.54
시가총액:
$3.44M
수익:
-
순이익/손실:
$-17.06M
주가수익비율:
-0.0783
EPS:
-70.7173
순현금흐름:
$-14.18M
1주 성능:
+5.52%
1개월 성능:
-16.06%
6개월 성능:
-47.75%
1년 성능:
-91.67%
1일 변동 폭
$5.37
$5.7364
1주일 범위
$5.18
$5.7364
52주 변동 폭
$4.93
$114.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
명칭
Cns Pharmaceuticals Inc
전화
1-800-946-9185
주소
2100 WEST LOOP SOUTH, HOUSTON
CNSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.54 | 3.29M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 개시 | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
CNS Pharmaceuticals Inc. (CNSP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 0.5% – Here’s Why - Defense World
Aug Reactions: How CNS Pharmaceuticals Inc stock performs in rate cut cycles2025 Top Gainers & Capital Efficient Trading Techniques - moha.gov.vn
CNS Pharmaceuticals names Rami Levin as new CEO following John Climaco’s departure - MSN
Whats Driving Tourism Finance Corporation of India Limited Stocks Recent Momentum Key TrendsCandlestick Trading Patterns & High Return Capital Strategies - earlytimes.in
Why CNS Pharmaceuticals Inc. stock is popular among millennialsJuly 2025 Update & Free Risk Controlled Daily Trade Plans - Улправда
Will CNS Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда
Is CNS Pharmaceuticals Inc. stock positioned well for digital economyQuarterly Earnings Report & High Conviction Buy Zone Picks - Улправда
CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 19, 2025) - GuruFocus
CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 18, 2025) - GuruFocus
CNS Pharmaceuticals appoints Rami Levin as new CEO, replacing Climaco By Investing.com - Investing.com South Africa
CNS Pharmaceuticals Announces New CEO Appointment - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Rami Levin as President and CEO - Digital Journal
CNS Pharmaceuticals Appoints Rami Levin as CEO to Advance Brain Cancer Pipeline - citybuzz -
CNS Pharmaceuticals shares dip after CEO departure announcement - MSN
CNS Pharmaceuticals appoints Rami Levin as CEO, John Climaco resigns By Investing.com - Investing.com Australia
CNS Pharmaceuticals appoints Rami Levin as CEO effective Jan 1, 2026 - marketscreener.com
CNS Pharmaceuticals stock falls after CEO steps down - Investing.com India
CNS Pharmaceuticals stock falls after CEO steps down By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals appoints Rami Levin as CEO, John Climaco resigns - Investing.com
CNS Pharmaceuticals Announces CEO Transition - TradingView — Track All Markets
CNS Pharmaceuticals (CNSP) appoints new CEO Rami Levin and outlines Climaco severance - Stock Titan
CNS Pharmaceuticals (CNSP) Appoints New CEO - GuruFocus
CNS Pharmaceuticals appoints Rami Levin as new CEO, replacing Climaco - Investing.com India
Brain cancer drug developer taps new CEO with global track record - Stock Titan
CNS Pharmaceuticals Earnings Notes - Trefis
Cycle buying Applied Therapeutics to develop CNS drugs - BioWorld MedTech
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 7th Annual CNS Delivery SummitSlideshow - Seeking Alpha
Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities CNS Therapeutics Virtual Conference 2025, Dec-08-2025 12 - marketscreener.com
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast - Digital Journal
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 (PRAX) - Seeking Alpha
CNS Pharmaceuticals CEO Outlines Strategy to Target Glioblastoma by Overcoming Blood-Brain Barrier - citybuzz
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Will CNS Pharmaceuticals Inc. stock gain from lower inflationGold Moves & High Accuracy Trade Alerts - Newser
CNS Pharma (CNSP) Stock Analysis Report | Financials & Insights - Benzinga
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
CNS Pharmaceuticals, Inc. (CNSP) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Alector to Participate in the Bank of America CNS Therapeutics Conference - Yahoo Finance
What analysts say about CNS Pharmaceuticals Inc stockGrowth vs. Value Investing & High Profit Investment Ideas - earlytimes.in
Where Analysts See Bemco Hydraulics Limited Stock by YearEndRisk-Reward Ratio Analysis & Free Rapid Return Acceleration - earlytimes.in
Bank of America CNS Therapeutics Virtual Conference - marketscreener.com
CNS Pharmaceuticals, Inc.Common Stock (NQ: CNSP - Markets Financial Content
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - The Manila Times
CNS Pharmaceuticals Increases Authorized Shares for Growth - The Globe and Mail
CNS Pharmaceuticals shareholders approve share increases and board elections at annual meeting - Investing.com Australia
CNS Pharmaceuticals shareholders approve share increases and board elections at annual meeting By Investing.com - Investing.com South Africa
Cns Pharmaceuticals Inc (CNSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):